Annexon expands vonaprument Phase 3 program with Month 24 endpoint
Adds dual primary endpoint and launches open-label extension study for geographic atrophy treatment.
Latest Annexon Biosciences News & Updates
See the latest news and media coverage for Annexon Biosciences. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of C1q inhibitors for complement-driven diseases
annexonbio.com- Headquarters
- South San Francisco, United States
- Founded year
- 2011
- Company type
- Public company
- Number of employees
- 100–200
- Industry
- Biotechnology & Medical Research
Last updated
Latest news about Annexon Biosciences
In short: Annexon Biosciences filed for regulatory approval of tanruprubart for GBS and progressed its Phase 3 program for geographic atrophy.
Company announcements
Annexon reports Q2 2026 financial results and business updates
BLA submission for tanruprubart expected in Q4 2026; vonaprument Phase 3 on track; $200M credit facility extends runway into 2028.
Annexon reports positive FORWARD data for tanruprubart in GBS
All ten treated patients improved within one week, including four bedbound patients who walked by day eight; supports Q4 2026 BLA submission.
Annexon secures up to $200M credit facility from Oxford Finance
The non-dilutive funding supports progress toward registration for vonaprument and tanruprubart.
Media coverage
Annexon at Cantor Fitzgerald conference: eye data, gbs progress By Investing.com
On Thursday, 10 September 2026, Annexon (ANNX) used the 12th Annual Cantor Fitzgerald Global Healthcare Conference to press its case as a complement-focused drug developer...
Vonaprument may protect from vision loss in geographic atrophy
In the phase 2 ARCHER study, vonaprument (Annexon Biosciences), formerly known as ANX007, decreased the number of patients with notable vision loss by approximately two-thirds...
Thousands of Americans live with this rare condition—New drug may give hope
The experimental drug could become the first approved treatment for Guillain-Barré syndrome, a paralyzing nerve disease.
Annexon shares fall as second-quarter loss exceeds Wall Street forecasts
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Never miss news about Annexon Biosciences
Track Annexon Biosciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Oculis
Ticketplus
HELP Therapeutics
CMC
ManpowerGroup
Arcosa
Alliance Entertainment
QXO
Reliant Stones
Amber
The Pool Tile Co
Cinajus
Armstone
Eco Outdoor
Sareen Stone
Stone Planet
Salience Labs
Trio Petroleum
Arianespace
American Eagle
AEO
OLB
Compass
MAQS
Roschier
Möller & Partners
Normain
Incentive Industrier
Pinecone
SSHL
Videobuddy
Founders Alliance
ITT
ServiceTitan